ALZHEIMER'S DISEASE: A COMPREHENSIVE REVIEW

被引:2
作者
Surabhi [1 ]
Singh, B. K. [1 ]
机构
[1] Kumaun Univ, Dept Pharmaceut Sci, Naini Tal 263001, Uttarakhand, India
关键词
Alzheimer's disease; Pathology; Risk factors; Protective factors; Biomarkers; Pharmacotherapy; OXIDATIVE STRESS; RISK-FACTORS; ASSOCIATION WORKGROUPS; DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; FUTURE; ACETYLCHOLINE; BIOMARKERS; EXERCISE; PATHOPHYSIOLOGY;
D O I
10.13040/IJPSR.0975-8232.10(3).993-00
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Alzheimer disease (AD) is the most common cause of dementia which affects more than 44 million individuals worldwide. It has been noticed that there is only symptomatic treatments are available to treat AD, but no cure exists. It is a neurodegenerative disease characterized by Alois Alzheimer's in 1906, and neurodegenerative diseases are one of the major concerns facing by the modern health care system. It is a multifarious complex disease which pathology not clearly understood but it is generally characterized by neuronal damage, memory dysfunction, etc. main pathological hallmark factor for Alzheimer disease is deposition of amyloid-beta (A beta) plaques around the neurons, neurofibrillary tangles, and a decrease in acetylcholine concentration and some other neurotransmitter dysregulation. Different types of risk factors like oxidative stress, obesity, diabetes, hypertension, air pollution, smoking, hyper cholesterolemia etc. have a very significant role in the development of AD and in the development of its preventive measures. Physical exercise and nutritional factors have been shown as protective measures for it and help in its prevention. For the diagnosis of it, we use cerebrospinal fluid biomarkers and positron emission tomography etc. Currently, there are two conventional pharmacotherapies exist for AD which is approved by Food and Drug Administration (FDA) are respectively- acetylcholinesterase inhibitors-tacrine, donepezil, rivastigmine, galantamine and N-methyl-D-aspartate glutamate antagonist (NMDA)-memantine.
引用
收藏
页码:993 / 1000
页数:8
相关论文
共 82 条
[1]   Obesity as a risk factor for Alzheimer's disease: weighing the evidence [J].
Alford, S. ;
Patel, D. ;
Perakakis, N. ;
Mantzoros, C. S. .
OBESITY REVIEWS, 2018, 19 (02) :269-280
[2]   2018 Alzheimer's disease facts and figures [J].
不详 .
ALZHEIMERS & DEMENTIA, 2018, 14 (03) :367-425
[3]   The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review [J].
Anand, Abhinav ;
Patience, Albert Anosi ;
Sharma, Neha ;
Khurana, Navneet .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 815 :364-375
[4]  
Apostolova Liana G, 2016, Continuum (Minneap Minn), V22, P419, DOI 10.1212/CON.0000000000000307
[5]   Early neurone loss in Alzheimer's disease: cortical or subcortical? [J].
Arendt, Thomas ;
Brueckner, Martina K. ;
Morawski, Markus ;
Jaeger, Carsten ;
Gertz, Hermann-Josef .
ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2015, 3 :10
[6]   Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function [J].
Arvanitakis, Z ;
Wilson, RS ;
Bienias, JL ;
Evans, DA ;
Bennett, DA .
ARCHIVES OF NEUROLOGY, 2004, 61 (05) :661-666
[7]   Neurodegenerative diseases and oxidative stress [J].
Barnham, KJ ;
Masters, CL ;
Bush, AI .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (03) :205-214
[8]   Alzheimer's Disease-Current Status and Future Directions [J].
Bhardwaj, Deepshikha ;
Mitra, Connie ;
Narasimhulu, Chandrakala Aluganti ;
Riad, Aladdin ;
Doomra, Mitsushita ;
Parthasarathy, Sampath .
JOURNAL OF MEDICINAL FOOD, 2017, 20 (12) :1141-1151
[9]   Acetylcholine: A neurotransmitter for learning and memory? [J].
Blokland, A .
BRAIN RESEARCH REVIEWS, 1995, 21 (03) :285-300
[10]  
Carter J., 2001, Current Molecular Medicine (Hilversum), V1, P733, DOI 10.2174/1566524013363177